Bicycle Therapeutics welcomes Pierre Legault to its Board of Directors as new Chairman

– UK, Cambridge / USA, MA –  Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today the appointment of Pierre Legault, MBA, CPA, as a Director and Chairman of the Board of Directors. Mr. Legault brings to Bicycle more than 35 years of executive leadership experience in the biopharmaceutical industry. He replaces Stephen J. Hoffman, M.D., Ph.D., as Chairman.

“I am excited to have Pierre join the Bicycle team. His broad experience in biopharma leadership will be tremendously valuable for us as our clinical pipeline matures,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “As we welcome Pierre, we also thank Steve for his guidance and leadership through a period of rapid growth at Bicycle over the last three years, helping us to successfully evolve the company into a clinical stage organization, complete two financings, establish a strong U.S. presence and develop a broad, differentiated product pipeline of Bicycle-based therapeutics.”

About Pierre Legault

Mr. Legault also currently serves as the Chairman of Poxel, a biopharmaceutical company developing innovative drugs for metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis. He is Chairman of Artios, a DNA damage repair company. He is also a member of the Board of Directors of Clementia Pharmaceuticals, Urovant Sciences and Syndax Pharmaceuticals. In the past, he was a member of the Board of Directors at Forest Laboratories, Tobira Therapeutics, NPS Pharmaceuticals, Regado Biosciences, Armo Biosciences, Iroko Pharmaceuticals, Cyclacel Pharmaceuticals, Eckerd Pharmacy and Nephrogenex, where he also served as the Chairman and CEO from 2012 to 2016. From 2010 to 2012, he served as the CEO of Prosidion. From 2009 to 2010, he served as the CFO and Treasurer of OSI Pharmaceuticals. Mr. Legault also served as the CEO of Eckerd Pharmacy and Senior Executive Vice President and CAO of the Rite Aid Corporation. Between 1989 and 2005, he held various global roles such as President, CEO and CFO of global group at Sanofi and legacy companies. Mr. Legault studied at McGill University, HEC Montreal and Harvard Business School.

“I’m honoured to accept this Chairman role,” said Mr. Legault. “Bicycle’s technology is truly unique, and I look forward to working closely with the team and the rest of the Board to advance our work in oncology and other diseases.”

About Bicycle Therapeutics

Bicycle Therapeutics is developing a unique class of chemically synthesised medicines based on its proprietary bicyclic peptide (Bicycle®) product platform to address therapeutic needs unreachable with existing treatment modalities. Bicycle’s internal focus is in oncology, where the company is developing targeted cytotoxics (Bicycle Toxin Conjugates®), targeted innate immune activators and T-cell modulators for cancers of high unmet medical need. Bicycles’ small size and highly selective targeting deliver rapid tumour penetration and retention while clearance rates and routes of elimination can be tuned to minimise exposure of healthy tissue and bystander toxicities. The company’s lead program, BT1718, is being evaluated in a Phase I/IIa trial in collaboration with Cancer Research UK. The company’s unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Greg Winter, a winner of the Nobel Prize in Chemistry for his pioneering work in phage display of peptides and antibodies, and Professor Christian Heinis. Bicycle has its headquarters in Cambridge, U.K., with many key functions and members of its leadership team located in the biotech hub of Boston, Mass.

For more, visit www.bicycletherapeutics.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.